Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment

Nuclear Medicine Communications

Volumn 33, Issue 1, 2012, Pages 90-96

  Liu, Congjin ^a   Brašić, James Robert ^c   Liu, Xingdang ^a   Li, Hongyu ^b   Xiang, Xueqin ^b   Luo, Zhifu ^b   Wang, Yuankai ^a   Kuai, Dayu ^a   Zhang, Guangming ^a   Zaknun, John J ^d  

^a FUDAN UNIVERSITY   (China)

^b CHINA INSTITUTE OF ATOMIC ENERGY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

bone seeking radiopharmaceuticals; camera acquisition settings; lutetium 177 EDTMP; radionuclide therapy; whole body imaging

Indexed keywords

LEXIDRONAM LUTETIUM LU 177; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PALLIATIVE THERAPY; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GAMMA CAMERAS; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TIME FACTORS; WHOLE BODY IMAGING;

EID: 82555205254     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834d3c13     Document Type: Article

References (21)

1. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987; 28:495-504. (Pubitemid 17074172)
2. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 2004; 31 (Suppl 1):S171-S178. (Pubitemid 38833047)
3. McEwan AJ. Pain from metastatic bone tumors. In: Aktolun C, Tauxe WN, editors. Nuclear oncology. Berlin: Springer-Verlag. 1999; pp. 245-260.
4. Daniel PP. Risk factors for the development of bone metastases in prostate cancer. Eur Urol 2007; 6 (Suppl):677-682.
5. Lewington VJ. A practical guide to targeted therapy for bone pain palliation. Nucl Med Commun 2002; 23:833-836.
6. Pauwels EK, Stokkel MP. Radiopharmaceuticals for bone lesions imaging and therapy in clinical practice. Q J Nucl Med 2001; 45:18-26. (Pubitemid 32586338)
7. Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:1023-1030. (Pubitemid 46919554)
8. Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000; 41:682-687. (Pubitemid 30207745)
9. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66:101-109. (Pubitemid 32521416)
10. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27:2429-2435.
11. 177Lu-EDTMP: A variable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm 2003; 23:202-213.
12. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl Med Commun 1998; 19:587-591. (Pubitemid 28319780)
13. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 2002; 23:67-74. (Pubitemid 34214308)
14. 188Re. Appl Radiat Isot 2001; 55:89-96. (Pubitemid 32322458)
15. Garnuszek P, Pawlak D, Licińska I, Kamińska A. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl Radiat Isot 2003; 58:481-488. (Pubitemid 36369436)
16. 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 2010; 37:215-226.
17. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63-69. (Pubitemid 24018442)
18. Vanzi E, Genovesi D, Di Martino F. Evaluation of a method for activity estimation in Sm-153 EDTMP imaging. Med Phys 2009; 36:1219-1229.
19. 177Lu nuclear reactions. Appl Radiat Isot 2008; 66:1218-1220.
20. 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008; 66:1196-1205.
21. 177Lu-EDTMP in patients with metastatic prostate cancer. J Nucl Med 2011; 52 (Suppl 1):1748.